Nitric oxide homeostasis as a target for drug additives to cardioplegia

British Journal of Pharmacology

Volumn 151, Issue 7, 2007, Pages 930-940

  Podesser, B K ^a   Hallstrom S ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cardioplegia; Heart; Ischemia reperfusion; Nitric oxide

Indexed keywords

ARGININE; BOSENTAN; BRADYKININ; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; CAPTOPRIL; CARDIOPLEGIC AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG ADDITIVE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN A RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; LISINOPRIL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PEPTIDE; QUINAPRILAT; S NITROSO HUMAN SERUM ALBUMIN; S NITROSOALBUMIN; S NITROSOCYSTEINE; S NITROSOGLUTATHIONE; S NITROSOGLUTATHIONE MONOETHYL ESTER; S NITROSOTHIOL; SUPEROXIDE; SUPEROXIDE DISMUTASE; TBC 1421; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE AGENT;

CARDIOPLEGIA; CHRONIC GRAFT REJECTION; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; DRUG TARGETING; ELECTRON TRANSPORT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME SUBSTRATE; ENZYME SYNTHESIS; HEART DISEASE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HEART SURGERY; HOMEOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CARDIOPLEGIC SOLUTIONS; FREE RADICAL SCAVENGERS; HOMEOSTASIS; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; REPERFUSION INJURY;

EID: 34547588608     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707272     Document Type: Review

References (124)

1. Ambrosio G, Flaherty JT, Duilio C, Tritto I, Santoro G, Elia PP et al. (1991). Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. J Clin Invest 87: 2056-2066.
2. Amrani M, Gray CC, Smolenski RT, Goodwin AT, London A, Yacoub MH (1997). The effect of L-arginine on myocardial recovery after cardioplegic arrest and ischemia under moderate and deep hypothermia. Circulation 96 (Suppl 9): II274-II279.
3. Arai H, Hori S, Aramori I, Ohkubo H, Nakashini S (1990). Cloning and expression of a cDNA encoding an endothelin receptor. Nature 3458: 730-732.
4. Azuma H, Ishikawa M, Sekizaki S (1986). Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 88: 411-415.
5. Balligand JL, Cannon PJ (1997). Nitric oxide synthases and cardiac muscle. Arterioscler Thromb Vasc Biol 17: 1846-1858.
6. Bates JN, Baker MT, Guerra Jr R, Harrison DG (1991). Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss is required. Biochem Pharmacol 42: 157-165.
7. Baue AE (1992). The horror autotoxicus and multiple-organ failure. Arch Surg 127: 1451-1462.
8. Baxter GF, Ebrahim Z (2002). Role of bradykinin in preconditioning and protection of the ischemic myocardium. Br J Pharmacol 135: 843-854.
9. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990). Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624.
10. Bhabra MS, Hopkinson DN, Shaw TE, Hooper TL (1997). Attenuation of lung graft reperfusion injury by a nitric oxide donor. J Thorac Cardiovasc Surg 113: 327-334.
11. Bilinska M, Maczewski M, Beresewicz A (1996). Donors of nitric oxide mimic effects of ischemic preconditioning on perfusion induced arrhythmias in isolated rat hearts. Mol Cell Biochem 161: 265-271.
12. Bolli R (1990). Mechanism of myocardial 'stunning'. Circulation 82: 723-738.
13. Bolli R (2001). Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33: 1897-1918.
14. Bonventura D, Oliveira FS, Tognioli V, Tedesco AC, da Silva RS (2004). A macrocyclic nitrosyl ruthenium complex is a NO donor that induces rat aorta relaxation. Nitric oxide 10: 83-91.
15. Boulanger C, Lüscher TF (1990). Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587-590.
16. Brady AJ, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE (1993). Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 265: H176-H182.
17. Braimbridge MV, Chayen J, Bitensky L, Hearse DJ, Jynge P, Cankovic-Darracott S (1977). Cold cardioplegia or continous coronary perfusion? Report on preliminary clinical experience as assessed cytochemically. J Thorac Cardiovasc Surg 74: 900-906.
18. Bretschneider HJ, Hubner G, Knoll D, Lohr B, Nordbeck H, Spieckermann PG (1975). Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. J Cardiovasc Surg (Torino) 16: 241-260.
19. Buckberg GD (1979). A proposed 'solution' to the cardioplegic controversy. J Thorac Cardiovasc Surg 77: 803-815.
20. Buckberg GD, Brazier JR, Nelson RL, Goldstein SM, MyConnell DH, Cooper N (1977). Studies of the effects of hypothermia on regional myocardial blood flow and metabolism during cardiopulmonary bypass. III. Effects of temperature, time, and perfusion pressure in fibrillating hearts. J Thorac Cardiovasc Surg 73: 87-94.
21. Carrier M, Pellerin M, Perrault LP, Bouchard D, Page P, Searle N et al. (2002). Cardioplegic arrest with L-arginine improves myocardial protection: results of a prospective randomized clinical trial. Ann Thoracic Surg 73: 837-842.
22. Carrier M, Pellerin M, Page PL, Searle NR, Martineau R, Caron C et al. (1998). Can L-arginine improve myocardial protection during cardioplegic arrest? Results of a phase I pilot study. Ann Thorac Surg 66: 108-112.
23. Caus T, Desrois M, Izquierdo M, Lan C, LeFur Y, Confort-Gouny S et al. (2003). NOS substrate during cardioplegic arrest and cold storage decreases stunning after heart transplantation in a rat model. J Heart Lung Transplant 22: 184-191.
24. Colagrande L, Formica F, Porta F, Martino A, Sangalli F, AvalLi L et al. (2006). Reduced cytokines release and myocardial damage in coronary artery bypass patients due to L-arginine cardioplegia supplementation. Ann Thoracic Surg 81: 1256-1261.
25. De Nucci G, Gryglewski RJ, Warner TD, Vane JR (1988). Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 85: 2334-2338.
26. Desrois M, Sciacky M, Lan C, Cozzone PJ, Bernard M (2000). L-arginine during long-term ischemia: effects on cardiac function, energetic metabolism and endothelial damage. J Heart Lung Transplant 19: 367-376.
27. Du ZY, Hicks M, Jansz P, Rainer S, Spratt P, Macdonald P (1998). The nitric oxide donor, diethylamine NONOate, enhances preservation of the donor rat heart. J Heart Lung Transplant 17: 1113-1120.
28. Dworschak M, Franz M, Hallström S, Semsroth S, Gasser H, Haisjackl M et al. (2004). S-nitroso human serum albumin improves oxygen metabolism during early reperfusion after severe myocardial ischemia. Pharmacol 72: 106-112.
29. Engelman DT, Watanabe M, Maulik N, Engelman RM, Rousou JA, Flack III JE et al. (1996). Critical timing of nitric oxide supplementation in cardioplegic arrest and reperfusion. Circulation 94 (Suppl 9): II407-II411.
30. Feelisch M, Schonafinger K, Noack E (1992). Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol 44: 1149-1157.
31. Feng J, Bianchi C, Sandmeyer JL, Sellke FW (2005). Bradykinin preconditioning improves the profile of cell survival proteins and limits apoptosis after cardioplegic arrest. Circulation 112: I190-I195.
32. Feng J, Li JY, Rosenkranz ER (2000). Bradykinin protects the heart after cardioplegic ischemia via NO-dependent mechanisms. Ann Thoracic Surg 70: 2119-2124.
33. Feng J, Sellke ME, Ramlawi B, Boodhwani M, Clements R, Li J et al. (2006). Bradykinin induces microvascular preconditioning through the opening of calcium-activated potassium channels. Surgery 140: 192-197.
34. Ferrari R (1996). The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol 28: 1-10.
35. Ferrari R, Visioli O (1991). Protective effects of calcium antagonists against ischemia and reperfusion damage. Drugs 42 (Suppl 1): 14-26.
36. Furukawa Y, Matsumori A, Hirozane T, Sasayama S (1996). Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation 93: 333-339.
37. Garg UC, Hassid A (1989). Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83: 1774-1777.
38. Gewaltig MT, Kojda G (2002). Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 55: 250-260.
39. Gonon AT, Erbas D, Bröijerson A, Valen G, Pernow J (2004). Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 286: H1767-H1774.
40. Gottardi R, Szerafin T, Semsroth S, Trescher K, Wolner E, Hallström S et al. (2004). S-nitroso-human serum albumin improves organ preservation in orthotopic heart transplantation in the pig. J Heart Lung Transplant 23: 172 (Abstract).
41. Gourine AV, Gonon AT, Pernow J (2001). Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am J Physiol Heart Circ Physiol 280: H1105-H1112.
42. Grace PA (1994). Ischemia-reperfusion injury. Br J Surg 81: 637-647.
43. Griscavage JM, Hobbs AJ, Ignarro LJ (1995). Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 34: 215-234.
44. Guru V, Omura J, Alghamdi AA, Weisel R, Fremes SE (2006). Is blood superior to crystalloid cardioplegia? A meta-analysis of randomized clinical trails. Circulation 114: I331-I338.
45. Hallström S, Gasser H, Neumayer C, Fügl A, Nanobashvili J, Jakubowski A et al. (2002). S-nitroso human serum albumin treatment reduces ischemia/reperfusion injury in skeletal muscle via nitric oxide release. Circulation 105: 3032-3038.
46. Hartman JC (1995). The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 60: 789-792.
47. 4. Mol Genet Metab 86 (Suppl 1): 2-10.
48. Hatori N, Sjöquist PO, Marklund SL, Pehrsson SK, Ryden L (1992). Effects of recombinant human extracellular-superoxide dismutase type-c on myocardial reperfusion injury in isolated cold-arrested rat hearts. Free radical Biol Med 13: 137-142.
49. Hatta E, Rubin LE, Seyedi N (1997). Bradykinin and cardioprotection: don't set your heart on it. Pharmacol Res 35: 531-536.
50. Hayashida N, Tomoeda H, Oda T, Tayama E, Chihara S, Akasu K et al. (2000). Effects of supplemental L-arginine during warm blood cardioplegia. Ann Thorac Cardiovasc Surg 6: 27-33.
51. Hess ML, Manson NH (1984). Molecular oxygen: friend and foe. The role of the oxygen free radical system in the calcium paradox, the oxygen paradox and ischemia/reperfusion injury. J Mol Cell Cardiol 16: 969-985.
52. Hishikawa K, Lüscher TF (1997). Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation 96: 3610-3616.
53. Huk I, Nanobashvili J, Neumayer C, Punz A, Mueller M, Afkhampour K et al. (1997). L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation 96: 667-675.
54. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G (1987). Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84: 9265-9269.
55. Jahania MS, Sanchez JA, Narayan P, Lasley RD, Mentzer Jr RM (1999). Heart preservation for transplantation: principles and strategies. Ann Thorac Surg 68: 1983-1987.
56. Johnson III G, Tsao PS, Lefer AM (1991). Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit Care Med 19: 244-252.
57. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T (2002). Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 40: 521-527.
58. Kanai AJ, Mesaros S, Finkel MS, Oddis CV, Birder LA, Malinski T (1997). Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol 273: C1371-C1377.
59. Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Mori H et al. (1995). Beneficial effects of inhibition of angiotensin-concerting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 92: 950-961.
60. Kiziltepe U, Tunctan B, Eyileten ZB, Sirlak M, Arikbuku M, Tasoz R et al. (2004). Efficiency of L-arginine enriched cardioplegia and non-cardioplegic reperfusion in ischemic hearts. Int J Cardiol 97: 93-100.
61. Klein HH, Schubothe M, Nebendahl K, Kreuzer H (1984). The effects of two different diltiazem treatments on infarct size in ischemic reperfused porcine hearts. Circulation 69: 1000-1005.
62. Kojda G, Kottenberg K (1999). Regulation of basal myocardial function by NO. Cardiovasc Res 41: 514-523.
63. Koller PT, Bergmann SR (1989). Reduction of lipid peroxidation in reperfused isolated hearts by diltiazem. Circ Res 65: 838-846.
64. Konorev EA, Joseph J, Tarpey MM, Kalyanaraman B (1996). The mechanism of cardioprotection by S-nitrosoglutathione monoethyl ester in rat isolated heart during cardioplegic ischaemic arrest. Br J Pharmacol 119: 511-518.
65. Korn P, Kröner A, Schirnhofer J, Hallström S, Bernecker O, Mallinger R et al. (2002). Quinaprilar during cardioplegic arrest prevents ischemia-reperfusion injury. J Thorac Cardiovasc Surg 124: 352-360.
66. Korthuis RJ, Granger DN, Townsley MI, Taylor AE (1985). The role of oxygen - derived free radicals in ischemia induced increases in canine skeletal muscle vascular permeability. Circ Res 57: 599-609.
67. Kourembanas S, Marsden PA, McQuillan LP, Faller DV (1991). Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 88: 1054-1057.
68. Kröner A, Seitelberger R, Schirnhofer J, Bernecker O, Mallinger R, Hallström S et al. (2002). Diltiazem during reperfusion preserves high-energy phosphates by protection of mitochondrial integrity. Europ J Cardio Thorac Surg 21: 224-231.
69. Langford EJ, Brown AS, Wainwright RJ, de Belder AJ, Thomas MR, Smith RE et al. (1994). Inhibition of platelet activity by S- nitrosoglutathione during coronary angioplasty. Lancet 344: 1458-1460.
70. Laude K, Thuillez C, Richard V (2001). Coronary endothelial dysfunction after ischemia and reperfusion: a new therapeutic target? Braz J Med Biol Res 34: 1-7.
71. Lazar H, Volpe C, Bao Y, Rivers S, Vita JA, Keany Jr JF (1998). Beneficial effects of angiotensin-converting enzyme inhibitors during acute revascularization. Ann Thorac Surg 66: 487-492.
72. Linz W, Wiemer G, Schoelkens BA (1992). ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects ischemic rat hearts. J Mol Cell Cardiol 24: 909-919.
73. Loke KE, McConnell PI, Tuzman JM, Shesely EG, Smith CJ, Stackpole CJ et al. (1999). Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res 84: 840-845.
74. Ma XL, Weyrich AS, Lefer DJ, Lefer AM (1993). Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 72: 403-412.
75. Malinski T, Taha Z (1992). Nitric oxide release from a single cell measurement in situ by a porphyrinic based microsensor. Nature 358: 676-678.
76. Marks GS, McLaughlin BE, Jimmo SL, Poklewska-Koziell M, Brien JF, Nakatsu K (1995). Time-dependent increase in nitric oxide formation concurrent with vasodilation induced by sodium nitroprusside, 3-morpholinosydnonimine and S-nitroso-N-acetyl-penicillamine but not by glyceryl trinitrate. Drug Metab Dispos 23: 1125-1252.
77. Mayers I, Salas E, Hurst T, Johnson D, Radomski MW (1999). Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by S-nitrosoglutathione. J Thorac Cardiovasc Surg 117: 1009-1016.
78. Melrose DG, Dreyer B, Bentall HH, Baker JB (1955). Elective cardiac arrest. Lancet 269: 21-22.
79. Moncada S, Palmer RM, Higgs EA (1991). Nitric oxide: phsiology, pathophsiology and pharmacology. Pharmacol Rev 43: 109-142.
80. 2 receptor activation in human heart. J Am Coll Cardiol 29: 1559-1606.
81. Münzel T, Daiber A, Ullrich V, Mülsch A (2005). Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscl Thromb Vasc Biol 25: 1551-1557.
82. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T (2002). Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 109: 735-743.
83. Nelson SK, Gao B, Bose S, Rizeq M, McCord JM (2002). A novel heparin-binding, human chimeric, superoxide dismutase improves myocardial preservation and protects from ischemia-reperfusion injury. J Heart Lung Transplant 21: 1296-1303.
84. Oliveira FS, Tognioli V, Pupo TT, Tedesco AC, da Silva RS (2004). Nitrosyl ruthenium complex as nitric oxide delivery agent: synthesis characterization and photochemical properties. Inorg Chem Commun 7: 160-164.
85. Paulus WJ, Shah AM (1999). NO and cardiac diastolic function. Cardiovasc Res 43: 595-606.
86. Perrault LP, Nicker C, Desjardins N, Dumont E, Thai P, Carrier M (2001). Improved preservation of coronary endothelial function with Celsior compared with blood and crystalloid solutions in heart transplantation. J Heart Lung Transplant 20: 549-558.
87. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al., Basket-Late Investigators (2006). Late clinical events after discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48: 2592-2595.
88. Pinsky DJ, Oz MC, Koga S, Taha Z, Broekman MJ, Marcus AJ et al. (1994). Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Invest 93: 2291-2297.
89. Podesser BK, Schirnhofer J, Bernecker OJ, Kröner A, Franz M, Semsroth S et al. (2002). Optimizing I/R-injury in the failing rat heart improved myocardial protection with acute ACE inhibition. Circulation 106: I277-1283.
90. Podesser BK, Zegner M, Weisser J, Koci G, Kunold A, Hallström S et al. (1996). Vergleich dreier gängiger Kardioplegielösungen- Untersuchungen am isolierten Herz zur Myokardprotektion während Ischämie und Reperfusion. Acta Chirurg Austriaca 28: 17-28.
91. Radomski MW, Palmer RMJ, Moncada S (1987). Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2: 1057-1058.
92. Ramzy D, Rao V, Mallidi H, Tumiati LC, Xu N, Miriuka S et al. (2005). Cardiac allograft preservation using donor-shed blood supplemented with L-arginine. J Heart Lung Transplant 24: 1665-1672.
93. Recchia FA, McConnell PI, Loke KE, Xu X, Ochoa M, Hintze TH (1999). Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res 44: 325-332.
94. Redondo J, Manso AM, Pacheco ME, Hernandez L, Salaices M, Marin J (2000). Hypothermic storage of coronary endothelial cells reduces nitric oxide synthase activity and expression. Cryobiology 41: 292-300.
95. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K et al. (1990). Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348: 732-735.
96. Sandstrom J, Carlson L, Marklund SL, Edlund T (1992). The heparin binding domain of extra cellular superoxide dismutase-c and formation of varients with reduced heparin affinity. J Biol Chem 267: 18205-18209.
97. Sauaia MG, de Lima RG, Tedesco AC, da Silva RS (2003). Photo-induced NO release by visible light irradation from pyrazine-bridged nitrosyl ruthenium complexes. J Am Chem Soc 125: 14718-14719.
98. Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP et al. (1997). Local intramural delivery of L-arginine enheances nitric oxide generation and inhibits lesion formation after balloon angiplasty. Circulation 95: 1863-1869.
99. Seitelberger R, Hannes W, Gleichauf M, Keilich M, Christoph M, Fasol R (1994). Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting. J Thorac Cardiovasc Surg 107: 811-821.
100. Sellke FW, DiMaio MJ, Caplan LR, Ferguson TB, Gardner TJ, Hiratzka LF et al. (2005). Comparing on-pump and off-pump coronary artery bypass grafting. Circulation 111: 2858-2864.
101. Semsroth S, Fellner B, Trescher T, Bernecker OY, Kalinowski L, Gasser H et al. (2005). S-nitroso human serum albumin attenuates ischemia/reperfusion injury after prolonged cardioplegic arrest in isolated rabbit hearts. J Heart Lung Transplant 24: 2226-2234.
102. Shumway NE, Lower RR, Stofer RC (1959). Selective hypothermia of the heart in anoxic cardiac arrest. Surg Gynecol Obstet 109: 750-754.
103. Siegfried MR, Carey C, Ma XL, Lefer AM (1992). Beneficial effects of SPM-5185, a cysteine-containing NO donor in myocardial ischemia-reperfusion. Am J Physiol 263: H771-H777.
104. Sjöquist PO, Carlson L, Jonason G, Marklund SL, Abrahamson T (1991). Cardioprotective effects of recombinant human extracellular-superoxide dismutase type C in rat isolated heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol 17: 678-683.
105. Southard JH (1995). Organ preservation. Ann Rev Med 46: 235-247.
106. Sternbergh WC, Makhoul RG, Adelman B (1993). Nitric oxide mediated endothelium dependent vasodilatation is selectively attenuated in the postischemic extremity. Surgery 114: 960-967.
107. Tadokoro H, Miyazaki A, Satomura K, Ryden L, Kaul S, Kar S et al. (1996). Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occlusion/reperfusion porcine heart model. J Cardiovasc Pharmacol 28: 134-141.
108. Takano H, Tang XL, Qiu Y, Guo Y, French BA, Bolli R (1998). Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. Circ Res 83: 73-84.
109. The GISSI-3 APPI study Group (1996). Early and six month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI study). Am J Cardiol 78: 1191-1197.
110. Trescher K, Bauer M, Dietl W, Gottardi R, Hallström S, Wick N et al. (2006). Improvement of cardioprotection by the selective endothelin-A-receptor antagonist TBC-3214Na: acute versus long-term blockade. Interact Cardiovasc Thorac Surg 5 O55-I (Abstract).
111. Valantine HA (2003). Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant 'atheroma'. Transplantation 76: 891-899.
112. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H et al. (1998). Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 95: 9220-9225.
113. Verma S, Maitland A, WEisel RD, Fedak PW, Pomroy NC, Li SH et al. (2002). Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. J Thorac Cardiovasc Surg 123: 1074-1083.
114. Wang YX, Legzdins P, Poon JS, Pang CC (2000). Vasodilator effects of organotransition-metal nitrosyl complexes, novel nitric oxide donors. J Cardiovascular Pharmacol 35: 73-77.
115. Weis M, Cooke JP (2003). Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol 23: 567-575.
116. Wirth KJ, Linz W, Weimer G, Schoelkens BA (1997). Kinins and cardioprotection. Pharmacol Res 35: 527-530.
117. Wright CE, Rees DD, Moncada S (1992). Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 26: 48-57.
118. Wu KK (2002). Regulation of endothelial nitric oxide synthase activity and gene expression. Ann NY Acad Sci 962: 122-130.
119. Xia Y, Zweier JL (1997). Direct measurement of nitric oxide generation from nitric oxide synthase. Proc Natl Acad Sci USA 94: 12705-12710.
120. Xu KY, Kuppusamy SP, Wang JQ, Li H, Cui H, Dawson TM et al. (2003). Nitric oxide protects cardiac sarcolemmal membrane enzyme function and ion active transport against ischemiainduced inactivation. J Biol Chem 278: 41798-41803.
121. Yamashiro S, Noguchi K, Kuniyoshi Y, Koya K, Sakanashi M (2003). Role of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. J Cardiovasc Surg 44: 37-49.
122. Yamashita M, Schmid RA, Ando K, Cooper JD, Patterson GA (1996). Nitroprusside ameliorates lung allograft injury. Ann Thorac Surg 62: 791-796.
123. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415.
124. Zahler S, Kupatt CH, Becker BF (1999). ACE inhibition attenuates cardiac cell damage and preserves release of NO in the post-ischemic heart. Immunopharmacology 44: 27-33.